Klacid Xl (Clarithromycin)

Clarithromycin is a macrolide antibiotic used to treat bacterial infections across several organ systems.

• Community‑acquired pneumonia: eliminates the causative bacteria and improves respiratory function.
• Acute bacterial sinusitis: reduces sinus inflammation by eradicating pathogenic microbes.
• Skin and soft‑tissue infections: clears susceptible Staphylococcus and Streptococcus species.
• Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of triple‑therapy regimens.
• Other susceptible bacterial infections: provides coverage for a broad spectrum of Gram‑positive and some Gram‑negative organisms.

• Clarithromycin binds to the 50S subunit of bacterial ribosomes, blocking the translocation step of protein synthesis. This inhibition prevents peptide chain elongation, resulting in a bacteriostatic effect that limits bacterial growth and allows host immune mechanisms to clear the infection.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: transient gastrointestinal upset.
• Diarrhea: often mild to moderate in intensity.
• Abdominal pain: cramping or discomfort in the stomach area.
• Taste disturbance: altered or metallic taste perception.
• Headache: mild to moderate headache episodes.
• Vomiting: occasional emesis, usually self‑limiting.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• QT interval prolongation: may lead to cardiac arrhythmias.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Clostridioides difficile‑associated diarrhea: severe colitis risk.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions.
• Severe arrhythmias: including torsades de pointes.

Before initiating clarithromycin therapy, consider the following safety measures.

• Assess renal and hepatic function: adjust therapy if impairment is present.
• Monitor cardiac status: be vigilant for QT prolongation, especially in patients with cardiac risk factors.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Use caution with concomitant CYP3A4 substrates: monitor for altered drug levels.
• Pregnancy and lactation: safety data are limited; weigh benefits against potential risks.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Clarithromycin interacts with several medications; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase clarithromycin concentrations and toxicity.
• QT‑prolonging agents (e.g., quinidine, sotalol): combined use raises the risk of serious cardiac arrhythmias.
• Warfarin: clarithromycin can enhance anticoagulant effect, leading to elevated INR.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce clarithromycin efficacy.
• Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): monitor for signs of myopathy.
• Oral contraceptives: possible reduction in contraceptive effectiveness; consider alternative methods.